Company To Update Investors On Activities Surrounding Commercial Launch Of Lead Product
DALLAS, TX and NEW YORK, NY June 28, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), President and CEO Jeffrey B. Davis will present at the One Med Forum: Emerging Company Finance Conference on Wednesday, June 30th at 9:20 AM ET. The conference is being held at the Roosevelt Hotel in New York City.
Davis will provide an overview of Access’ clinical development programs and update investors on commercialization launch activities for its lead product, MuGard – a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Access Pharmaceuticals, Inc. is gearing up for the North American commercial launch set for late summer.
Read more »
MuGard Clinical Experience Reflects Delayed Onset, Significant Reduction in Pain, and Ease-of-Use in the Management of Oral Mucositis and Stomatitis
DALLAS, TX and New York, NY June 24, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy. To date, clinical experience shows that MuGard provides significant clinical benefit and is effective in the management of oral mucositis/stomatitis as well as other conditions of the oral cavity involving erythema. Key points from the poster include:
Read more »
Company Provides Update on MuGard™ Commercial Launch Activities
DALLAS, TX and New York, NY June 22, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is sponsoring an Oral Mucositis Symposium today for researchers and health care professionals attending the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. later this week. In an effort to further educate and build awareness of the debilitating side effect of anticancer treatments, the Oral Mucositis (OM) Symposium will feature leading industry experts covering various topics concerning the disease, from pathogenesis and clinical factors to prevention and management of oral mucositis. The OM Symposium is being held from 8:30 AM – 5:30 PM at the British Columbia Cancer Research Centre in Vancouver.
Read more »
Initiative Provides Full-Course MuGard Supportive Care Therapy for 500 Cancer Patients
DALLAS, TX and NEW YORK, NY June 15, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has initiated a broad-scale MuGard Centers-of-Excellence Sampling Program with leading oncology networks for its lead product, MuGard, a FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
Read more »
Company To Give Two Presentations Highlighting the Advances of Its Cobalamin Technology For Targeted RNAi Delivery Application
DALLAS, TX, June 10, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Senior VP of R&D, David Nowotnik, Ph.D., will give two presentations today on the Company’s Cobalamin siRNA program at the Novel Nanodelivery of siRNA and miRNA Symposium, hosted by the California NanoSystems Institute (CNSI) of UCLA. Access Pharma’s invited oral presentation and its poster presentation will highlight the cell targeting aspects of the Company’s proprietary Cobalamin technology and the progress made by its scientist team in applying that technology to the intracellular delivery of RNAi therapeutics.
Read more »
Digg!
Del.icio.us
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See